Introduction
============

Alzheimer's disease (AD) is one of the main causes of dementia among elderly individuals, and is characterized by memory impairments and loss of cognitive functions, which eventually leads to complete incapacity and death of patients within 3--9 years after diagnosis.[@b1-cia-9-1031] As the elderly population continues to grow, the prevalence of AD has increased remarkably worldwide. At present, AD is one of the leading causes of disability and death among the elderly.[@b2-cia-9-1031]--[@b4-cia-9-1031] AD has emerged as a serious public health concern, affecting patients' quality of life and placing an immense burden on the individual, family, and community. Therefore, elucidating the pathogenesis and risk factors of AD is of great significance for early detection, prevention, and control of the susceptible population.

Genetic, metabolic, and environmental factors play a role in the development and progression of AD.[@b5-cia-9-1031] Recent genome-wide association studies have identified many genetic variances and single-nucleotide polymorphisms (SNPs) that are associated with AD risk.[@b6-cia-9-1031] Estrogen-receptor gene polymorphisms are possible candidates for AD susceptibility. In women, estrogen loss associated with menopause status has been suggested to contribute to the development of AD.[@b7-cia-9-1031],[@b8-cia-9-1031] Estrogen has been shown to act as a neuroprotectant and a neurotrophic agent.[@b9-cia-9-1031] Estrogen promotes neuronal cell survival, reduces neuronal injury, protects against neurotoxins, facilitates axonal sprouting and neuronal repair, and enhances synaptic transmission and neurogenesis.[@b10-cia-9-1031] Recently, estrogen-replacement therapy has been proposed as a therapeutic approach to reduce the risk of developing AD and help patients with AD maintain their cognitive function.[@b11-cia-9-1031] Estrogen exerts most of its effects through at least two major classes of receptors -- estrogen receptor a (ESR1) and estrogen receptor β (ESR2).[@b12-cia-9-1031] Human *ESR1*, a member of the nuclear receptor superfamily of ligand-activated transcription factors, is located on human chromosome 6q25, and is one of the key mediators of hormonal response in estrogen-sensitive tissues. After binding to estrogen, ESR1 acts as a transcriptional factor that regulates gene expression and function by interacting with regulatory regions of target genes.[@b13-cia-9-1031] Many studies have demonstrated that *ESR1* polymorphisms might influence *ESR1* expression and affect estrogen function. To date, associations between *ESR1* polymorphisms and cancer,[@b14-cia-9-1031],[@b15-cia-9-1031] coronary artery disease,[@b16-cia-9-1031] hip fracture,[@b17-cia-9-1031] and bone mineral density[@b18-cia-9-1031] have been identified.

Accumulating evidence has demonstrated that two of the most widely studied SNPs in *ESR1* -- *PvuII* (T/C, rs223493) and *Xbal* (A/G, rs9340799) -- are possibly associated with AD. However, the results of studies seeking associations of *ESR1* with AD risk have not always been consistent in different population analyses.[@b19-cia-9-1031] Therefore, we performed a meta-analysis of all eligible studies to provide a more comprehensive and reliable conclusion by evaluating the association between *ESR1* gene polymorphisms and susceptibility to AD.

Materials and methods
=====================

Search strategy
---------------

We searched PubMed, Embase, Web of Science, Science Direct, SpringerLink, and the Chinese National Knowledge Infrastructure databases for eligible studies assessing the association of *ESR1* polymorphisms and AD risk (last search updated to November, 2013). The search terms were "Alzheimer's disease (AD) or dementia" in combination with "estrogen receptor or oestrogen receptor or estrogen" in combination with "polymorphism or variant or mutation". There was no restriction on time period, sample size, population, language, or type of report in order to minimize potential publication bias.

Inclusion and exclusion criteria
--------------------------------

Studies included in this meta-analysis had to meet the following criteria: 1) case-control studies or cohort studies, 2) studies investigating the association between *ESR1* gene polymorphisms and AD risk, 3) sufficient data available to calculate an odds ratio (OR) with 95% confidence interval (CI), and 4) clinical diagnosis of AD based on standards of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association. The exclusion criteria of the meta-analysis were: 1) case-control studies not focusing on the correlation between *ESR1* polymorphisms and AD risk; 2) insufficient original data was available for data extraction; and 3) meta-analyses, letters, reviews, and editorial articles. If more than one study was published by the same author using the same patient population, the study with the largest size of samples was included.

Data extraction
---------------

Two authors (DC and BL) independently extracted the data from all eligible publications based on the inclusion criteria. The following information was recorded: name of first author, year of publication, country, ethnicity, number of cases and controls, the source of control, genotype method, distribution of genotypes, and Hardy--Weinberg equilibrium in controls. According to the source of control, eligible studies were defined as hospital-based and population-based. Ethnicity was simply categorized as Asian or Caucasian. Discrepancies were resolved by consensus and by consulting a third author.

Statistical analysis
--------------------

Crude ORs with their corresponding 95% CIs were used to assess the strength of association between *ESR1* polymorphisms and AD risk. The statistical significance of pooled ORs was assessed by the *Z*-test. Statistical heterogeneity across studies included in the meta-analysis was assessed by Cochran's *Q* statistic and the *I*^2^ test.[@b20-cia-9-1031] *P*\<0.10 and *I*^2^\>50% were considered to be statistically significant heterogeneity, and the random-effects model or the fixed-effects model were used. Sensitivity analysis was performed using the leave-one-out method to test the reliability of the overall pooled results.[@b21-cia-9-1031] Publication bias was evaluated by funnel plot[@b22-cia-9-1031] and further assessed by Egger's linear regression test,[@b23-cia-9-1031] and *P*\<0.05 was considered representative of statistically significant publication bias. Data analyses were performed using Stata 11.0 (StataCorp, College Station, TX, USA) and RevMan 5.0 (Cochrane, Oxford, UK).

Results
=======

Eligible studies
----------------

A flowchart of the process of study selection is shown in [Figure 1](#f1-cia-9-1031){ref-type="fig"}. Based on the inclusion and exclusion criteria, a total of 17 articles were included in the meta-analysis after full-text review.[@b9-cia-9-1031],[@b24-cia-9-1031]--[@b39-cia-9-1031] The main characteristics of included studies are presented in [Table 1](#t1-cia-9-1031){ref-type="table"}. Of the 18 case-control studies included in the 17 articles, 18 studies investigated the *ESR1 PvuII* polymorphism (3,902 cases and 9,290 controls) and 17 studies investigated the *ESR1 XbaI* polymorphism (2,841 cases and 8,094 controls). Eight studies were performed in Caucasian populations,[@b9-cia-9-1031],[@b24-cia-9-1031],[@b25-cia-9-1031],[@b29-cia-9-1031]--[@b31-cia-9-1031],[@b36-cia-9-1031],[@b37-cia-9-1031] and ten studies were performed in Asian populations.[@b26-cia-9-1031]--[@b28-cia-9-1031],[@b32-cia-9-1031]--[@b35-cia-9-1031],[@b37-cia-9-1031]--[@b39-cia-9-1031] The genotype distributions among the controls of all studies were in agreement with the Hardy--Weinberg equilibrium, except for one study for the *ESR1 PvuII* polymorphism[@b25-cia-9-1031] and one study for the *ESR1 XbaI* polymorphism.[@b34-cia-9-1031]

Quantitative data synthesis
---------------------------

The results of this meta-analysis are presented in [Table 2](#t2-cia-9-1031){ref-type="table"}. The heterogeneity was significantly observed under all models (*P*\<0.05) for the *ESR1 PvuII* and *XbaI* polymorphisms, which might have resulted from differences in ethnicity, country, source of controls, and genotype methods, so the random-effects model was used.

For the *ESR1 PvuII* polymorphism, a total of 18 studies including 3,902 cases and 9,290 controls were included in the meta-analysis. In the overall analysis, we did not find any significant association between the *ESR1 PvuII* polymorphism and AD risk in any comparison model (C allele versus T allele, OR 1.05, 95% CI 0.95--1.17, *P*=0.35; CC + CT versus TT, OR 1.13, 95% CI 0.98--1.32, *P*=0.10; CC versus CT + TT, OR 0.95, 95% CI 0.80--1.13, *P*=0.60; CC versus TT, OR 1.03, 95% CI 0.84--1.28, *P*=0.75; CT versus TT, OR 1.15, 95% CI 1.00--1.33, *P*=0.05). Subgroup analysis stratified by ethnicity showed a significant association between the *ESR1 PvuII* polymorphism and AD risk under the dominant model (CC + CT versus TT, OR 1.14, 95% CI 1.02--1.28, *P*=0.03; [Figure 2](#f2-cia-9-1031){ref-type="fig"}) and heterozygous comparison (CT versus TT, OR 1.16, 95% CI 1.02--1.31, *P*=0.02), whereas no evidence of association was found under the allele model (C allele versus T allele, OR 1.06, 95% 0.98--1.15, *P*=0.12), recessive model (CC versus CT + TT, OR 1.01, 95% CI 0.88--1.15, *P*=0.89), or homozygous comparison (CC versus TT, OR 1.10, 95% CI 0.94--1.28, *P*=0.23) in Caucasian populations. Nevertheless, we did not find any significant association between the *ESR1 PvuII* polymorphism and AD risk under any model in the Asian population (all *P*\>0.05).

For the *ESR1 XbaI* polymorphism, a total of 17 studies including 2,841 cases and 8,094 controls were included in the meta-analysis. Overall, there was no evidence of an association between the *ESR1 XbaI* polymorphism and AD risk in different genetic models when all the eligible studies were pooled into the meta-analysis (G allele versus A allele, OR 1.05, 95% CI 0.90--1.23, *P*=0.53; GG + GA versus AA, OR 1.07, 95% CI 0.89--1.30, *P*=0.47 \[[Figure 3](#f3-cia-9-1031){ref-type="fig"}\]; GG versus GA + AA, OR 1.00, 95% CI 0.75--1.34, *P*=0.99; GG versus AA, OR 1.04, 95% CI 0.74--1.45, *P*=0.84; GA versus AA, OR 1.04, 95% CI 0.93--1.16, *P*=0.50). The association of the *ESR1 XbaI* polymorphism with AD was further stratified by ethnicity. Neither Caucasian populations nor Asian populations showed a significant association between the *ESR1 XbaI* polymorphism and AD risk in any model (all *P*\>0.05) ([Figure 3](#f3-cia-9-1031){ref-type="fig"}).

Sensitivity analysis
--------------------

A sensitivity analysis was performed to assess the influence of each individual study on the pooled ORs through omitting individual studies. Statistically similar results were obtained after sequentially excluding each study, suggesting the stability of this meta-analysis.

Publication bias
----------------

The shapes of the funnel plots did not reveal any evidence of obvious asymmetry visually under the dominant model of *PvuII* and *XbaI* polymorphisms ([Figure 4](#f4-cia-9-1031){ref-type="fig"}). Also, there was no statistical evidence of publication bias among studies using Egger's regression test for the *PvuII* (*P*=0.296) and *XbaI* (*P*=0.206) polymorphisms.

Discussion
==========

The *ESR1* gene is critical for hormone binding, deoxyribonucleic acid binding, and activation of transcription, because it encodes an estrogen receptor that is key in the mediation of hormonal response in estrogen-sensitive tissues.[@b40-cia-9-1031] Given that the effect of a hormone is given by the interaction with its receptor, genetic changes in the *ESR1* gene may lead to differences in *ESR1* expression and estrogen metabolism, and thereby possibly explain interindividual differences in cognitive impairment or AD risk. Several SNPs have been identified in *ESR1*, and among these identified SNPs, *PvuII* (T/C, rs2234693) and *XbaI* (A/G, rs9340799), which are located in intron 1 of the *ESR1* gene, 397 and 351 base pairs upstream of exon 2, respectively, are the most studied. Many previous genetic studies have investigated the function of *ESR1 PvuII* and *XbaI* polymorphisms in the etiology of AD, but the results remain inconclusive. Bertram et al reported that *ESR1 PvuII* and *XbaI* polymorphisms were associated with AD risk, and the *ESR1* gene could be a candidate gene in the development of AD using a systematic meta-analysis.[@b41-cia-9-1031] Another meta-analysis by Luckhaus and Sand indicated that *ESR1 PvuII* and *XbaI* polymorphisms were confirmed to modulate susceptibility to AD in Asian individuals, but not in Europeans.[@b42-cia-9-1031] However, only eleven studies and eight studies were included in Bertram et al's and Luckhaus and Sand's studies, respectively. Therefore, we performed a meta-analysis to update previous meta-analyses, and provide a more comprehensive and reliable analysis of the association between *ESR1 PvuII* and *XbaI* polymorphisms and AD risk.

This meta-analysis included 18 case-control studies with 3,902 cases and 9,290 controls for the *PvuII* polymorphism, and 17 case-control studies with 2,841 cases and 8,094 controls for the *XbaI* polymorphism. In the overall analysis, the *ESR1 PvuII* polymorphism was not associated with AD risk. In the analysis stratified by ethnicity, the *ESR1 PvuII* polymorphism was associated with AD susceptibility in Caucasian populations, while there was no evidence of an association between the *ESR1 PvuII* polymorphism and AD risk in Asian populations, which suggested that the differences in genetic background may affect AD susceptibility due to different ethnicities with different allele frequencies. Although the exact mechanism of the *PvuII* polymorphism in the development of AD is not yet clear, a possible reason could be that the *PvuII* polymorphism produces a binding site for a specific transcription factor that may affect gene expression,[@b43-cia-9-1031] while the presence of the C allele in the *PvuII* site was associated with decreased *ESR1* transcription and, consequently, a low number of receptors.[@b44-cia-9-1031] However, neither Caucasian populations nor Asian populations showed statistically significant associations between the *ESR1 XbaI* polymorphism and AD risk. Given that the *PvuII* and *XbaI* polymorphisms are in strong linkage disequilibrium,[@b45-cia-9-1031] it is difficult to determine which of the two polymorphic sites is driving the association. In our meta-analysis, the results suggested that the *ESR1 PvuII* polymorphism may be of importance in AD risk in Caucasian populations. These findings are not consistent with previous meta-analyses;[@b41-cia-9-1031],[@b42-cia-9-1031] our results indicated that only the *ESR1 PvuII* polymorphism may alter the risk of AD in Caucasian populations, not in Asian populations, suggesting multiple and different genes are involved in the pathophysiological process of AD in different ethnicities.

Several limitations should not be ignored when interpreting the results. First, all eligible studies were from Caucasian and Asian populations; therefore, our results were limited to these two populations. More studies containing the full range of possible ethnic differences are needed to avoid selection bias. Second, AD is a multifactorial disease involving complex gene--gene or gene--environment interactions. In this study, we had insufficient data to evaluate such interactions for the independent role of *ESR1* polymorphisms in AD risk. Third, we did not perform subgroup analysis by sex, age, or different stage of AD, due to limited data in primary studies. Fourth, because only published studies were included in this study, publication bias may have occurred, even though no statistical test bias was found.

Conclusion
==========

In summary, this meta-analysis indicates that the *ESR1 PvuII* polymorphism is associated with increased AD risk in Caucasian populations, but not in Asian populations. However, no significant association was observed for the *ESR1 XbaI* polymorphism and AD risk. This result should be interpreted cautiously. To confirm or refute this result, well-designed studies with larger sample sizes and more ethnic groups are required to elucidate this association further.
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![Flowchart of study selection.\
**Abbreviations:** *ESR1, estrogen receptor α*.](cia-9-1031Fig1){#f1-cia-9-1031}

![Forest plots of *ESR1 PvuII* polymorphism and Alzheimer's disease risk in Caucasian and Asian populations (dominant model, CC + CT versus TT).\
**Notes:** A random model of meta-analysis was employed for calculation of the combined ORs and *P*-values. Caucasian population, OR 1.14, CI 1.02--1.28, *P*=0.03; Asian population, OR 1.23, CI 0.91--1.67, *P*=0.18. The study of Maruyama et al[@b37-cia-9-1031] was performed in Asian populations (**a**), and Caucasian populations (**b**).\
**Abbreviations:** M-H, Mantel-Haenszel; OR, odds ratio; CI, confidence interval; *ESR1, estrogen receptor α*.](cia-9-1031Fig2){#f2-cia-9-1031}

![Forest plots of *ESR1 XbaI* polymorphism and Alzheimer's disease risk in Caucasian and Asian populations (dominant model, GG + GA versus AA).\
**Notes:** Random model of meta-analysis was employed for calculation of the combined ORs and *P*-values. Caucasian population, OR 1.03, CI 0.83--1.28, *P*=0.78; Asian population, OR 1.14, CI 0.82--1.57, *P*=0.44. The study of Maruyama et al[@b37-cia-9-1031] was performed in Asian populations (**a**), and Caucasian populations (**b**).\
**Abbreviations:** M-H, Mantel-Haenszel; CI, confidence interval; OR, odds ratio; *ESR1, estrogen receptor* *α*.](cia-9-1031Fig3){#f3-cia-9-1031}

![Egger's funnel plots of publication-bias analysis for the polymorphisms.\
**Notes:** (**A**) *ESR1 PvuII* polymorphism; (**B**) *ESR1 XbaI* polymorphism.\
**Abbreviations:** SE, standard error; OR, odds ratio; *ESR1, estrogen receptor* *α*.](cia-9-1031Fig4){#f4-cia-9-1031}

###### 

Characteristics of the 18 eligible studies included in the meta-analysis

  Study                               Year   Country                      Ethnicity   Source of controls   Sample size, (cases/controls)   SNP studied     Genotyping method   HWE
  ----------------------------------- ------ ---------------------------- ----------- -------------------- ------------------------------- --------------- ------------------- --------------
  Brandi et al[@b24-cia-9-1031]       1999   Italy                        Caucasian   PB                   193/202                         *PvuII, XbaI*   PCR-RFLP            0.827, 0.364
  Boada et al[@b25-cia-9-1031]        2012   Spain                        Caucasian   PB                   1,069/1,215                     *PvuII*         Real-time PCR       0.024
  Lambert et al[@b9-cia-9-1031]       2001   UK                           Caucasian   PB                   186/405                         *PvuII, XbaI*   PCR-RFLP            0.943, 0.159
  Lin et al[@b26-cia-9-1031]          2003   People's Republic of China   Asian       PB                   30/125                          *PvuII, XbaI*   PCR-RFLP            0.841, 0.051
  Ji et al[@b27-cia-9-1031]           2000   Japan                        Asian       PB                   234/134                         *PvuII, XbaI*   PCR-RFLP            0.659, 0.679
  Usui et al[@b28-cia-9-1031]         2006   Japan                        Asian       PB                   205/92                          *PvuII, XbaI*   PCR-RFLP            0.385, 0.150
  Corbo et al[@b29-cia-9-1031]        2006   Italy                        Caucasian   PB                   277/212                         *PvuII, XbaI*   PCR-RFLP            0.193, 0.512
  Monastero et al[@b30-cia-9-1031]    2006   Italy                        Caucasian   PB                   172/172                         *PvuII, XbaI*   PCR-RFLP            0.445, 0.062
  Porrello et al[@b31-cia-9-1031]     2006   Italy                        Caucasian   PB                   131/109                         *PvuII, XbaI*   PCR-RFLP            0.103, 0.751
  Li et al[@b32-cia-9-1031]           2004   People's Republic of China   Asian       PB                   66/143                          *PvuII, XbaI*   PCR-RFLP            0.288, 0.867
  Xu and Jia[@b33-cia-9-1031]         2002   People's Republic of China   Asian       PB                   49/55                           *PvuII, XbaI*   PCR-RFLP            0.736, 0.869
  Hou[@b34-cia-9-1031]                2009   People's Republic of China   Asian       PB                   203/138                         *PvuII, XbaI*   PCR-RFLP            0.798, 0.036
  Deng et al[@b35-cia-9-1031]         2013   People's Republic of China   Asian       HB                   236/236                         *PvuII, XbaI*   PCR-RFLP            0.240, 0.475
  den Heijer et al[@b36-cia-9-1031]   2004   Netherlands                  Caucasian   PB                   230/5,514                       *PvuII, XbaI*   Taqman              0.802, 0.627
  Maruyama et al[@b37-cia-9-1031]     2000   Japan                        Asian       PB                   183/133                         *PvuII, XbaI*   PCR-RFLP            0.068, 0.061
  Maruyama et al[@b37-cia-9-1031]     2000   UK                           Caucasian   PB                   156/120                         *PvuII, XbaI*   PCR-RFLP            0.903, 0.661
  Ma et al[@b38-cia-9-1031]           2009   People's Republic of China   Asian       PB                   219/215                         *PvuII, XbaI*   PCR-RFLP            0.424, 0.962
  Zhou et al[@b39-cia-9-1031]         2008   People's Republic of China   Asian       PB                   63/70                           *PvuII, XbaI*   PCR-RFLP            0.858, 0.142

**Abbreviations:** PB, population-based; HB, hospital-based; HWE, Hardy--Weinberg equilibrium; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SNP, single-nucleotide polymorphism.

###### 

Association between *ESR1* polymorphisms and Alzheimer's disease risk

                      Allele model                   Dominant model   Recessive model             Homozygous comparison   Heterozygous comparison                                                           
  ------------------- ------------------------------ ---------------- --------------------------- ----------------------- --------------------------- ------ ------------------- ------ ------------------- ------
  ***PvuII* (T/C)**   **C allele versus T allele**                    **CC** + **CT versus TT**                           **CC versus CT** + **TT**          **CC versus TT**           **CT versus TT**    
  Overall             1.05 (0.95--1.17)              0.35             1.13 (0.98--1.32)           0.10                    0.95 (0.80--1.13)           0.60   1.03 (0.84--1.28)   0.75   1.15 (1.00--1.33)   0.05
  Caucasian           1.06 (0.98--1.15)              0.12             1.14 (1.02--1.28)           0.03                    1.01 (0.88--1.15)           0.89   1.10 (0.94--1.28)   0.23   1.16 (1.02--1.31)   0.02
  Asian               1.06 (0.87--1.30)              0.55             1.23 (0.91--1.67)           0.18                    0.84 (0.61--1.17)           0.31   0.98 (0.65--1.47)   0.91   1.28 (0.95--1.72)   0.10
  ***XbaI* (A/G)**    **G allele versus A allele**                    **GG** + **GA versus AA**                           **GG versus GA** + **AA**          **GG versus AA**           **GA versus AA**    
  Overall             1.05 (0.90--1.23)              0.53             1.07 (0.89--1.30)           0.47                    1.00 (0.75--1.34)           0.99   1.04 (0.74--1.45)   0.84   1.04 (0.93--1.16)   0.50
  Caucasian           1.02 (0.85--1.22)              0.84             1.03 (0.83--1.28)           0.78                    1.00 (0.70--1.42)           0.99   1.01 (0.67--1.53)   0.97   1.03 (0.88--1.20)   0.71
  Asian               1.10 (0.84--1.43)              0.50             1.14 (0.82--1.57)           0.44                    1.03 (0.62--1.70)           0.92   1.09 (0.62--1.91)   0.78   1.13 (0.83--1.55)   0.44

**Abbreviations:** *ESR1*, *estrogen receptor α*; OR, odds ratio; CI, confidence interval.
